publication date: Aug. 30, 2014


html Lymphoma.html

Researchers Find Two Types of MCL Drug Resistance


Genomic analyses of tissues from mantle cell lymphoma patients helped researchers explain two types of drug resistance and ways to overcome them in the clinic.

In the study—published in Cancer Discovery, a journal of the American Association for Cancer Research—researchers examined mantle cell lymphoma patients that failed to respond to treatment with ibrutinib (Imbruvica), or initially responded, but then stopped and progressed.

“Ibrutinib, a drug that targets a protein called BTK, shows unprecedented clinical activity against mantle cell lymphoma,” said Selina Chen-Kiang, professor of pathology and laboratory medicine and professor of microbiology and immunology at Weill Cornell Medical College. “However, the drug doesn’t work for about 32 percent of patients, and their lymphomas are said to have primary resistance to ibrutinib. We are also learning that most patients whose lymphomas respond to ibrutinib eventually relapse because their tumors acquire resistance to the drug.”

“The knowledge that we gained from longitudinal RNA and genomic sequencing of mantle cell lymphomas with primary and acquired resistance to ibrutinib allowed us to identify rational drug combinations that may overcome resistance in these two settings,” continued Chen-Kiang. “We recently opened a clinical trial to test one of these combinations, the selective CDK4/6 inhibitor palbociclib and ibrutinib [NCT02159755].”

Researchers used whole-exome and whole-transcriptome analysis of five serial biopsies from a patient who had mantle cell lymphoma that initially responded to ibrutinib before progressing to identify reasons why mantle cell lymphomas acquire resistance to ibrutinib.

After comparing these data with results from analysis of healthy tissues from the same patient, the researchers found that a mutation in BTK, the C481S mutation, … Continue reading CCL August – Lymphoma

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.